Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
How would you manage T3N0M0 sarcomatoid carcinoma of the prostate with Adenosquamous differentiation s/p prostatectomy?
Any role for adjuvant therapy with chemotherapy, ADT or radiation?
Related Questions
What are your top takeaways from ASCO GU 2025?
How do you manage PSA progression while a patient is on xofigo or pluvicto?
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
What duration androgen deprivation do you recommend with salvage pelvic radiotherapy for pelvic node relapse after prostatectomy?
How do you interpret recent large retrospective analyses comparing radical prostatectomy vs. radiation for prostate cancer?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?
Why is there a benefit of ADT for high risk prostate cancer treated with radiation, yet no large trials describing benefit of adjuvant ADT after radical prostatectomy?
How do you reconcile discordant PSMA and MRI findings in patients undergoing definitive radiotherapy for prostate cancer?
Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?